Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...

Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...

UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq

Firefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024 FAIRFAX, Va. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing...

Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer FAIRFAX, Va. and TORONTO, June 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”), a pioneering artificial intelligence (“AI”) driven company developing innovative...